BriaCell Therapeutics Corp is an immuno-oncology biotechnology company based in Berkeley, California. They are focused on developing a targeted and less toxic approach to cancer management, specifically for late-stage cancer patients with limited treatment options. Their lead product, BriaVax, is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line, which aims to generate strong immune responses to recognize and eliminate cancer cells.
The company has already shown promising clinical results in previous FDA Phase I trials, with some patients experiencing significantly longer survival rates than expected. BriaCell is committed to advancing BriaVax through additional FDA-approved clinical trials to provide hope and treatment options for cancer patients. Their mission is to harness the body's immune system to selectively destroy cancer cells while sparing normal cells, ultimately preventing cancer recurrence.
Generated from the website